Hepatitis C virus (HCV) is both hepatotropic and lymphotropic and has been shown to be associated with the benign lymphoproliferative disorder, mixed cryoglobulinemia (MC). Preliminary studies suggest that there may be an association between chronic hepatitis C, MC, and non-Hodgkin's lymphoma (NHL). The aim of this study was to determine whether patients with chronic HCV and MC have occult bone marrow NHL. Sixteen patients with chronic HCV and clinically active MC underwent bone marrow biopsy and aspiration. Flow cytometry was performed looking for abnormal B-cell lineage. Molecular genetic studies were performed to identify B-cell monoclonality. Nine of 16 patients (56%) had abnormal marrow morphology, 7 (44%) were interpreted as suspicious for lymphoma, and 2 (13%) as consistent with lymphoma. Flow cytometry on 13 patients identified 5 (39%) with increased B-cell populations. Molecular analysis on 13 patients identified 3 (23%) with monoclonal proliferation of the B-cell lineage. All 13 patients tested for Epstein-Barr virus were negative by polymerase chain reaction (PCR). Four of 16 patients (25%) had marrow morphology and evidence of a monoclonal B-cell population by flow cytometry and/or molecular studies, consistent with B-cell NHL. These findings confirm the presence of lymphoproliferative disorders in patients with chronic HCV and MC. Some of these disorders meet the morphological and molecular criteria for the diagnosis of malignant lymphoma. (HEPATOLOGY 1999;29:543-547.) 
Chronic hepatitis C virus (HCV) infection has been associated with a number of nonhepatic clinical conditions, including essential mixed cryoglobulinemia (MC). 1 In addition, HCV-RNA sequences and replicative forms of the virus have been isolated from peripheral blood mononuclear cells, which suggests that the virus is both hepatotropic and lymphotropic, 2 thus supporting the etiologic link between HCV and cryoglobulinemia.
Cryoglobulinemia is a chronic multisystem disorder characterized by deposition of circulating immune complexes in small-and medium-size vessels, giving rise to the clinical picture of palpable purpura, Raynaud' s syndrome, arthralgias, peripheral neuropathy, and glomerulonephritis. 3 It is usually classified among the benign lymphoproliferative disorders, and is associated with chronic polyclonal B-lymphocyte proliferation. It has been postulated that HCV leads directly to the benign lymphoproliferative process, and then secondarily to the syndromes of MC caused by the cold-reacting paraprotein. 1, 4 Recently, Pozzato et al. reported an association of chronic HCV, cryoglobulinemia, and low-grade nonHodgkin' s lymphoma (NHL). 5 Two other recent studies reported the presence of HCV infection in a substantial number of unselected NHL patients. 6, 7 The aim of the present work was to determine the frequency of occult NHL in our patients with chronic HCV and clinically active cryoglobulinemia using similar methodology. In addition, we undertook molecular genetic analyses to increase the sensitivity of identifying monoclonal populations.
PATIENTS AND METHODS
The study protocol was approved by the Toronto Hospital Committee for Research on Human Subjects, and each patient gave informed written consent before entry. Twenty-four patients with chronic hepatitis C and clinically active cryoglobulinemia were identified at one tertiary referral liver clinic, and 16 of the 24 consented to participation in the study. All patients underwent a complete history and physical examination to document the symptoms and physical findings related to mixed cryoglobulinemia, and to rule out symptoms or physical findings of malignant lymphoma.
There is no accepted scoring system available to assess the severity of disease in cryoglobulinemia. Therefore, we defined minor disease as the presence of sparse skin lesions occurring intermittently. Moderate disease was defined as more extensive skin lesions, with or without ulceration or Raynaud' s syndrome, arthritis, or peripheral neuropathy not causing disability. Severe disease included debilitating vasculitic lesions, peripheral neuropathy, or renal disease with abnormal serum creatinine and creatinine clearance.
Routine laboratory examination for all patients included a complete blood count with differential white blood cell count, prothrombin time and partial thromboplastin time, biochemistry including liver function tests, serum protein electrophoresis, quantitative serum immunoglobulins, serum complement levels, rheumatoid factor, and microscopic urinalysis. All patients were tested for the presence of anti-HCV antibodies (IMX MEIA kits; Abbott, Mississauga, Ontario, Canada), and HCV RNA by polymerase chain reaction (PCR) (Qualitative Amplicor HCV PCR test; Roche, Mississauga, Ontario, Canada). Serological tests for hepatitis B virus and human immunodeficiency virus were performed on all patients using standard protocols. Three patients had bone marrow procedures before entry into the study, and they were not subjected to repeat testing. Thus, molecular genetics and cellular flow analysis were not available on these 3 patients. The remaining patients underwent both aspiration and biopsy from the posterior iliac crest using Jamshidi needles and standard techniques.
For cryoglobulin measurements, 10 mL of blood was incubated at 37°C for 2 days, and then 4 mL of serum was separated and stored for 10 days at 4°C. The cryoprecipitates were then fractionated according to standard methods. Using the standard immune protein electrophoresis technique, cryoprecipitate levels higher than 5% were all characterized as type II (IgM kappa paraprotein complexed with polyclonal IgG).
Pathological interpretation of bone marrow aspirates and biopsies was performed by a single hematopathologist (D.P.). Three distinct morphological subtypes were defined for classification: 1) normal marrow with no evidence of lymphoid infiltrates; 2) benign lymphoid foci, consisting of small lymphocytes or small irregular lymphoid cells present focally throughout the marrow and not in a paratrabecular location in the core biopsy. The infiltrates had to show no tendency to extend out into the intervening interstitial hematopoietic tissue. On cytological examination, there could be no evidence of malignant atypia, and changes seen were considered reactive in nature rather than malignant. 3) Focal lymphocytic infiltrates consistent with lymphoma; these were to consist of multiple infiltrates of small irregular lymphoid cells, sometimes with small, cleaved cells in which a paratrabecular location was observed in the biopsy.
For molecular genetic analysis, DNA was extracted from the bone marrow for Southern analysis using a probe specific for the immunoglobulin heavy-chain gene. B-cell monoclonality and the presence of Epstein-Barr virus were also assessed using PCR. DNA extraction and precipitation and Southern blot analysis were performed using standard protocols. [8] [9] [10] For PCR analysis, 1 µg of DNA was amplified using the appropriate primers, electrophoresed through a 2% agarose gel, and visualized using ethidium bromide. Appropriate positive, negative, and internal controls were run with each specimen. PCR analysis to assess the clonality of the B-cell lineage was performed essentially as described by Trainor et al. 11, 12 The presence of Epstein-Barr virus was assessed using primers specific for the BamW1 region of the virus ( 5Ј GTT CGC GTT GCT AGG CCA CC 3Ј and 5Ј AGG ACC ACT TTA TAC AG GC 3Ј ). The fidelity of the DNA used and of the PCR reaction was checked in all cases using internal controls, as previously described. 13 For cellular flow analysis, a 100-µL aliquot of cell suspension was added to an appropriate monoclonal antibody combination. A whole-blood lysis method using Optilyse C Lysing Solution (Immunotech, Marseille, France) was used as a fixative and to eliminate red blood cells. Lymphocyte phenotypes were determined using twoand three-color direct immunofluorescence and the Coulter Epics XL (Coulter Corporation, Miami, FL) flow cytometer equipped with an argon laser emitting 488 nm. Lymphocytes were ''gated'' using a forward-scatter versus side-scatter histogram. All flow cytometry data were analyzed by Coulter Epics XL, System 11, version 1.0 software. The following monoclonal antibodies were used in relevant combinations and conjugated with either fluorescein isothiocyanate, phycoerythrin, or an energy-coupled dye: CD3, CD4, CD5, CD7, CD8, CD10, CD19, CD20, CD23, CD34, CD45, FMC7 (Coulter Corporation), CD2, CD3, CD11c, HLA-DR (Becton Dickinson), and kappa and lambda light chain (DAKO Corporation, Carpinteria, CA).
RESULTS
Only patients with chronic hepatitis C with clinical manifestations suggestive of cryoglobulinemia were tested for cryoglobulins. From a population of approximately 1,500 patients with chronic HCV, 16 of 24 who tested positive for cryoglobulins agreed to participate in the study. There were 11 males and 5 females (median age, 57 years; range, 40-74 years). Their clinical characteristics and severity of cryoglobulinemia are summarized in Table 1 . The mean duration of clinically active cryoglobulinemia was 6.5 years (range, 2-10 years).
Baseline laboratory parameters are also shown in Table 1 . Six patients had evidence of mild anemia (hemoglobin Ͻ120 g/L), and 7 patients had thrombocytopenia (platelets Ͻ150 ϫ 10 6 /L). No study patient had an absolute lymphocytosis. Serum protein electrophoresis identified a polyclonal increase in immunoglobulins in 5 patients. Complement levels were depressed in 7 patients. Three patients were noted to have renal involvement with raised serum creatinine and at least 1 g/L of proteinuria in 24 hours. All patients had nonreactive human immunodeficiency virus tests, and only 1 patient had serology consistent with previous hepatitis B infection.
The results of the bone marrow morphology, cellular flow analyses, and molecular genetic analyses are summarized in Tables 2 and 3 . Nine of 16 patients (56%) had abnormal bone marrow morphology. Seven (44%) of the samples demonstrated focal lymphoid aggregates that were interpreted as suspicious for lymphoma, but only 2 (13%) had lymphoid aggregates, which morphologically were classified as consistent with lymphoma (Table 2) .
Cellular flow analysis identified 5 of 13 patients (39%) with increased B-cell populations. Only 2 (15%) had clonal (kappa light chain) B-cell populations, and the other 3 had abnormally increased nonclonal B-cell populations showing increased CD10 expression (Table 3) .
Molecular genetic analysis by PCR on DNA extracted from bone marrow cells identified a B-cell monoclonal proliferation in 3 of 13 (23%) patients (Table 3) . Southern analysis using a probe specific for the immunoglobulin heavy-chain gene confirmed this finding. All 13 bone marrow samples were negative for Epstein-Barr virus by PCR.
Only 1 patient had bone marrow morphology, flow cytometry, and molecular studies all consistent with B-cell NHL ( Figs. 1 and 2) . No systemic manifestations of NHL were present in this individual. One of 2 patients with monoclonality on molecular analysis showed an abnormal B-cell population on flow analysis; however, this was nonclonal. Their marrow morphology indicated lymphoid aggregates, suspicious for, but not diagnostic of, lymphoma. Three patients with abnormal cellular flow analysis studies had marrow morphology consistent with or suspicious of lymphoma. No patient with a morphologically normal bone marrow had either flow or molecular abnormalities detected. Follow-up bone marrow aspirates have been performed in 2 patients who were shown previously to have bone marrow morphology suspicious for lymphoma, 1 of whom has shown progression of his marrow involvement with lymphoma. In addition, this patient had a positive clonal population by molecular analysis on repeat testing, but no systemic involvement. All 16 patients are being seen regularly, and none have developed symptoms or signs of systemic lymphoma.
There was a trend toward increased severity of cryoglobulinemia (debilitating vasculitis with or without renal involvement or peripheral neuropathy) in the 9 patients who had bone marrow samples suspicious for lymphoma. Five of the 9 patients with abnormal bone marrows had severe disease, compared with only 1 of the 7 with a normal marrow (P ϭ .09). The duration of cryoglobulinemia did not seem to correlate with the presence or absence of abnormalities in bone marrow. All patients were HCV RNA-positive in serum and RNA titers, and genotyping was not performed.
DISCUSSION
The association between HCV infection and cryoglobulinemia has been reported previously, 1, 4 and viral genomic sequences of HCV have been found in both the sera and the peripheral lymphocytes of patients with cryoglobulinemia. 14 Cryoglobulinemia may arise as the result of a complex mechanism involving chronic stimulation of the immune NOTE. All patients with abnormal molecular and flow analysis had abnormal bone marrow morphology.
Four patients with B-cell clonal population either by molecular or flow analysis.
One patient had monoclonal B-cell and clonal population.
FIG. 1. Paratrabecular focus of small lymphoid cells with some extension into an adjacent hematopoietic marrow biopsy specimen. (Hematoxylin-eosin stain; original magnification ϫ400.) 1999 system by HCV, with the generation of monoclonal IgM anti-IgG rheumatoid factor. 15 Pozzato et al. were the first to describe the presence of low-grade NHL in bone marrow samples from patients with cryoglobulinemia attributed to HCV infection. 5 They reported that abnormal populations of lymphocytes were found in 23 of 31 patients (68%) examined, although only 12 (38%) had the features of malignant lymphoma. Our study results are similar in that 9 of 16 patients (56%) had bone marrow abnormalities that were felt to be either diagnostic or highly suspicious for lymphoma. Their study was performed on an Italian population, but our study confirms that this association between HCV, cryoglobulinemia, and NHL also exists outside Italy.
The morphological diagnosis of lymphoma from lymphoid infiltrates in the bone marrow alone may be difficult, because lymphoid infiltrates may reflect a response to acute or chronic immune stimulation. Differentiating benign from malignant lymphoid foci requires the demonstration of cellular atypia, a tendency for the lymphocytes to extend into the interstitial hematopoietic tissue, and the demonstration that the lymphocytes are a clonal population. The use of molecular genetic studies such as Southern analysis and PCR can further increase the probability of identifying B-cell monoclonality because of the sensitivity of these techniques.
The diagnosis of NHL was supported in the Pozzato study by flow cytometric confirmation of a monoclonal lymphoid population in 12 cases (30% of the study population). 5 In contrast, flow cytometry demonstrated a clonal population in only 2 of the 13 patients examined in our study (15%). But this does not exclude the possibility of a malignant lymphoproliferative process. Naughton et al. reported that flow cytometry was positive in only 56% of patients who had a confirmed diagnosis of malignant lymphoma in the bone marrow. 16 Our study is the first report of molecular analysis of bone marrow specimens from patients with HCV infection and cryoglobulinemia. Southern analysis can detect the presence of a monoclonal proliferation if it involves greater than 1% of the total cells present. PCR immunoglobulin heavy-chain gene primers can detect monoclonality in approximately 75% to 83% of B-cell neoplasms. Twenty-three percent of our study patients had a monoclonal proliferation of the B-cell lineage by PCR and Southern analysis. Even using these sensitive techniques, we were unable to confirm monoclonality in all of the patients with histological changes thought to be either diagnostic of, or suspicious for, lymphoma. Only 1 patient had histology, flow, and molecular findings consistent with NHL. Two patients who had suspicious marrows and nonclonal B-cell proliferation by flow were found to have monoclonal subpopulations by molecular techniques. In total, 4 of 13 marrow samples analyzed had a clonal population detected by one of the techniques employed.
The natural history of this clinical entity remains unclear, and it is not possible to make firm recommendations for therapy. None of our patients have so far demonstrated any symptoms or signs of disseminated lymphoma with follow-up to 2 years. Neither have any patients received chemotherapy. Pozzato et al. reported that 9 patients showed progression of lymphoproliferative disease during long-term follow-up. 5 In 5 cases, progression was based on the development of anemia, and 4 developed liver and spleen enlargement. It was unclear from their report whether these clinical observations truly were a result of the progression of lymphoma rather than of their underlying liver disease. Only 3 of their patients developed generalized lymphadenopathy showing either low-grade (one) or intermediate-grade (two) lymphoma on biopsy. Two Italian studies reported long-term follow-up, and both supported the notion that occult lowgrade lymphomas of the marrow may, over time, become systemic, and may also evolve into higher grades that might require systemic therapy. 5, 17 Ferri et al. identified 10 patients who developed NHL 1 to 11 years after the onset of cryoglobulinemia. 17 These patients were selected from a series of 200 patients with MC who had no previous documentation of hepatitis. The diagnosis of NHL was suspected on the basis of clinical symptoms and confirmed by lymph node biopsy with histological and immunophenotypic analyses. Isolation of HCV RNA from the serum and peripheral blood mononuclear cells in all 10 patients suggested a pathogenic role of HCV in the development of NHL. 17 Other retrospective screening studies have demonstrated the presence of HCV infection in 22% to 30% of unselected NHL patients who did not have symptomatic cryoglobulinemia. 6, 7 However, a study by our group showed that the prevalence of HCV infection in 100 patients with NHL was 1%, which was no different from a control population of patients with nonhematological malignancies. 18 In view of the apparent associations of lymphoproliferative disorders with HCV and cryoglobulinemia, it might be expected that the incidence of malignant lymphoma would be particularly high after liver transplantation. We have reviewed the cases of malignant lymphoma arising after liver transplantation at our institution over the past 10 years, and could detect no difference in the incidence of lymphoma between patients transplanted for liver failure secondary to hepatitis C or other nonviral causes. There were only two cases of lymphoma in patients transplanted for HCV, and neither gave a history of cryoglobulinemia.
In summary, we have confirmed the presence of occult lymphoproliferative disorders in patients with HCV and cryoglobulinemia. Clinical follow-up to date has not indicated systemic disease, but the full spectrum and natural history of this entity requires longer follow-up, and it will be important to determine whether monoclonal B-cell populations detected either by flow or molecular techniques predict progression to overt lymphoma.
